Business Wire

Solasia Announces License and Capital Alliance for SP-04 (PledOx®) with Maruho

Share

Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) announced today that it has entered into an exclusive license agreement with Maruho Co., Ltd. (Headquarters: Osaka, Japan, President & CEO: Koichi Takagi, hereinafter “Maruho”) for commercialization of Solasia’s product SP-04 (PledOx®, hereinafter “product”), a therapeutic agent for chemotherapy induced peripheral neuropathy (currently undergoing Phase III clinical trials; active ingredient name: calmangafodipir) in Japan.

Under the license agreement, Maruho will commercialize the product exclusively in Japan after Solasia completes development of the product. Based on the license agreement, Solasia will supply the product exclusively to Maruho, and Maruho will pay Solasia an upfront payment of 1.0 billion yen and milestone payments based on progress in development and marketing up to a total of 18.0 billion yen.

In addition to the above license agreement, Solasia and Maruho have entered into a capital alliance agreement whereby Maruho acquires Solasia shares by a third-party allotment with a view to maintain a close business relationship going forward.

Capital alliance format:

Acquisition of newly issued Solasia shares by Maruho in third-party allotment

Pay-in date:

December 26, 2019

Number of shares issued:

11,324,000 Solasia common stock

Issue price per share:

151 yen (closing price on December 9, 2019)

Total issue amount:

1,709,924,000 yen

Shareholding ratio after issue:

Maruho will hold 9.70% of outstanding shares in Solasia

Lock-up agreement:

 

Maruho must obtain prior consent from Solasia if transferring its shareholding before the day following the date of the initial announcement of the clinical trial results and others by Solasia after completion of the two Phase III trials of the product currently under way.

 

Solasia’s top shareholder, ITOCHU Corporation must obtain prior consent from Solasia if transferring its shareholding within one year of the pay-in date stated above.

Use of proceeds:

For in-licensing and development of new pipeline product SP-05.

Maruho specializes in dermatology and has contributed to improving the quality of life (QOL) of patients suffering from skin disorders caused by cancer treatment. This time, in order to further contribute to cancer patients and their families, Maruho decided to obtain the rights to commercialize the product. Solasia specializes in oncology in Asia, and 3 of their 4 existing and development products include drugs that treat the side effects of anticancer drugs. Solasia is yet to establish an in-house sales force in Japan. Therefore, in light of the steady progress of the phase III clinical trial for the product, Solasia decided to derive the commercialization rights to Maruho who share the common philosophy of the importance of improving patient QOL.

Koichi Takagi, President and CEO of Maruho, commented as follows:
“Solasia is a specialty pharmaceutical company in oncology. The company supports patients undergoing cancer treatment and their families by developing not only anticancer drugs, but also cancer supportive care products to improve patient QOL. In collaboration with Solasia, we will continue to do our best to help cancer patients and their families further by combining Solasia’s extensive knowledge in oncology with the experience we have gained in improving patient QOL.”

Yoshihiro Arai, President and CEO of Solasia, commented as follows:
“Maruho is a leading company in Japan in the dermatology area that has gained from many years’ experience with cancer and other patients the insight that improving patient QOL is as important as treating the underlying disease. We are confident that Maruho, with its wealth of knowledge and experience in patient QOL, is the best partner for Solasia, as we can broadly share the expectations and importance of our development product SP-04 in the treatment of chemotherapy-induced peripheral neuropathy and work together to improve patient QOL.”.

About Maruho
Please visit https://www.maruho.co.jp/english/

About Solasia
Please visit https://www.solasia.co.jp/en/

Chemotherapy Induced Peripheral Neuropathy
Please link to https://solasia.co.jp/en/pipeline/sp-04.html

SP-04 (PledOx®)
Please link to https://solasia.co.jp/en/pipeline/sp-04.html

Contact information

Solasia Pharma K.K.
Rie Toyoda, Public Relations and Investor Relations
Tel: +81 3 5843 8049 (TOKYO)
info@solasia.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Selected for German Lighting Brand Simprolux’s Human Centric Lighting23.9.2020 12:00:00 EESTPress release

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED technology, announced that its SunLike Series natural spectrum LEDs, which implement light that closely matches the spectrum of sunlight, has been adopted by German lighting brand Simprolux for its pendant luminaire “ORTUS”. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923005077/en/ Simprolux’s pendant luminaire “ORTUS” designed with SunLike Series natural spectrum LEDs (Photo: Business Wire) ORTUS is a premium product line that delivers residential lighting for dining table and study or work spaces, combining with Casambi Technologies Oy’s state-of-the-art automated wireless Bluetooth. With SunLike Series natural spectrum LEDs, the fixture are designed to bring out the natural color tones of objects achieving a lower blue light peak, similar to the sunlight spectral curve, which enables the reduction of scattered reflection and glare. It a

Arthur D. Little Announces New Board of Directors23.9.2020 11:00:00 EESTPress release

Following the completion of its ninth Partners’ and Shareholders’ Meeting since becoming a private partnership again in 2011, Arthur D. Little (ADL) today announces the new members of its Board of Directors. The Shareholders’ Meeting also re-elected Ignacio García Alves to serve a new tenure of three years as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923005336/en/ Arthur D. Little Board of Directors (Photo: Business Wire) The results of the 2020 digital elections for the Board of Directors, with each member to serve a tenure of three years, were as follows: Ignacio García Alves (Chairman) Rodolfo Guzman Yusuke Harada Thomas Kuruvilla Bernd Schreiber Ulrica Sehlstedt Nick White. Held this year as a digital event that included over 100 participants, the Partners’ and Shareholders’ Meeting was an opportunity to celebrate the company’s ongoing success and resilience in the face of an exceptionall

ABP Publishing, a European Market Leader Audiobook Publisher, Rose Superior to Coronacrisis and Increased Sales 65%23.9.2020 11:00:00 EESTPress release

ABP Publishing shares the results of the second quarter. They show a significant rise in popularity and interest to audiobooks. Based on the financial reports for the second quarter, the sales increased 65% compared with the same period of the previous year. The most impressive results have been achieved in the French market with doubled sales. Noteworthy, during the quarantine, the structure of the listeners' interests has changed. For instance, the audiobooks in the category Relationships and parenting were bought by 50% more often than before the lockdown. The listeners who had to spend more time with their families were searching for ways of comfortable and mutually respected communication with their significant others. As judged by reviews, ABP Publishing audiobooks were immensely helpful in such an unusual situation. Speaking of listeners' reviews, the average merit of ABP Publishing audiobooks at Audible is more than 4.5 out of 5.0. Moreover, the number of users have completed l

Former HSBC Group COO Andy Maguire Joins Thought Machine as New Chair23.9.2020 11:00:00 EESTPress release

Thought Machine, the cloud native core banking technology company today announces the appointment of Andy Maguire as Chair. Maguire, former Group Chief Operating Officer of HSBC, joins Thought Machine effective immediately. At HSBC, Maguire led the bank’s IT, business operations, change support, procurement and real estate services. Prior to HSBC, Maguire was Boston Consulting Group’s managing partner for the UK and Ireland, and a member of their global executive committee. Maguire’s appointment comes at a time of significant momentum for Thought Machine, which recently closed its series B round at $125m, the fourth largest fundraising round in UK fintech this year. Furthermore, Thought Machine has added more than 150 employees in 2020 and has made a number of key senior hires in Q2 including Nicole Jude as Chief People Officer. Nicole recently led HR and people functions at Diligent Corporation and Bloomberg. The appointment of Maguire happens against the backdrop of banks around the

Servify Raises $23 Million in Series C, Led by Iron Pillar23.9.2020 10:45:00 EESTPress release

Servify , the device lifecycle management platform that integrates multiple OEM Brands and their sales and service ecosystem to deliver great after-sales service experience today announced that they have raised $23M in Series C financing. This round was led by its existing investor Iron Pillar, an India focused venture growth investor from its recently concluded Top Up Fund. In addition to all the existing investors such as Blume, Beenext and Tetrao SPF, this funding round also saw participation from funds managed by Global Alternatives Investor 57 Stars, multiple strategic investors like Sparkle Fund (an investment arm of DMI Finance), SF Roofdeck Capital LLC (Investment arm of Silicon Valley Investment Bank FT Partners), Go Ventures (investment arm of Go PLC, a Maltese integrated telecommunications company) and Madhu Kela Family Office. Servify’s existing Venture Debt provider Trifecta Capital also participated in the round. Sreevathsa Prabhakar, Founder, Servify said, “It is very sa

ARTIFICIAL INTELLIGENCE and CLOUD: The First Edition of the Second Level Master’s From Politecnico di Torino and Reply Will Begin in January 202123.9.2020 10:30:00 EESTPress release

Enrolment for the Politecnico di Torino Master’s in "Artificial Intelligence & Cloud: Hands-on Innovation", created by Reply, is now open. The unique educational programme has been developed to offer highly qualified students a professional specialization in the IT sector through its most innovative technologies: artificial intelligence and cloud. Starting in January 2021, the Master’s will last 12 months. Modules in the first semester - which will be taught on campus at Politecnico di Torino - will alternate between professors from Politecnico di Torino and Reply specialists, in a combination of theoretical lessons and development experiences. In the second semester students will carry out a 6-month work project at Reply, where they will be able to put into practice the knowledge acquired in the classroom by working within teams on live projects. The entire course is in English and open to international entrants. The first edition of the Master’s will be open to students with a Master

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom